ACM
TXG icon

Asymmetry Capital Management’s 10x Genomics TXG Stock Holding History

Asymmetry Capital Management’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-37,587
Closed -$5.32M – 41
2020
Q4 		$5.32M Sell
37,587
-5,925
-14% -$860K 2.43% 16
2020
Q3 		$5.42M Sell
43,512
-7,307
-14% -$767K 3.49% 15
2020
Q2 		$4.54M Buy
50,819
+26,216
+107% +$2.04M 3.48% 11
2020
Q1 		$1.53M Buy
+24,603
New +$1.92M 1.68% 22

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
MCAV
Meritech Capital Associates V Palo Alto, California $141M AUM 15.44% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Asymmetry Capital Management's TXG Position: Q1 2021 in Review

Asymmetry Capital Management sold out of 10x Genomics (TXG) in Q1 2021, closing a stake of 37,587 shares — an estimated $5.32M sold.

Asymmetry Capital Management first reported a position in TXG in Q1 2020 and held it in 4 quarters. The position peaked at $5.42M in Q3 2020. 324 funds tracked by Wall St. Rank hold TXG as of Q1 2021.

  • Asymmetry Capital Management reported no remaining 10x Genomics position as of Q1 2021 after selling out during the quarter.
  • Asymmetry Capital Management sold 37,587 10x Genomics shares in Q1 2021, an estimated $5.32M.
  • Asymmetry Capital Management first reported a position in 10x Genomics in Q1 2020 and held it in 4 quarters.
  • Asymmetry Capital Management's 10x Genomics position peaked at $5.42M in Q3 2020.
  • 324 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2021.

Based on Asymmetry Capital Management's 13F filing for Q1 2021, filed 11 May 2021.